Adult Refsum disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:773OMIM:266500G60.1
Who is this for?
Show terms as
23Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Adult Refsum disease (ARD), also known as classic Refsum disease, heredopathia atactica polyneuritiformis, or phytanic acid storage disease, is a rare inherited disorder of lipid metabolism caused by the accumulation of phytanic acid in blood and tissues. The condition results from a deficiency of the peroxisomal enzyme phytanoyl-CoA hydroxylase (encoded by the PHYH gene) or, less commonly, defects in the PEX7 gene, which is required for importing the enzyme into peroxisomes. Phytanic acid, a branched-chain fatty acid derived exclusively from dietary sources (dairy products, ruminant fats, and certain fish), cannot be properly broken down and accumulates in multiple organ systems. The disease primarily affects the nervous system, eyes, skin, heart, and bones. Cardinal clinical features include retinitis pigmentosa (causing progressive night blindness and visual field constriction), peripheral polyneuropathy (with distal weakness, sensory loss, and absent deep tendon reflexes), cerebellar ataxia, and elevated cerebrospinal fluid protein without increased cell count (albuminocytologic dissociation). Additional features may include ichthyosis (dry, scaly skin), anosmia (loss of smell), sensorineural hearing loss, cardiac arrhythmias and cardiomyopathy, and skeletal abnormalities such as shortened metacarpals or metatarsals. Symptoms typically begin in late childhood or early adulthood, though onset is variable. The cornerstone of treatment is strict lifelong dietary restriction of phytanic acid, which involves limiting intake of dairy fats, ruminant meat fat, and certain fish. When adhered to consistently, dietary management can lower plasma phytanic acid levels, stabilize or improve neurological symptoms, and prevent disease progression. Plasmapheresis or lipid apheresis may be used in acute situations or when phytanic acid levels are dangerously elevated, to rapidly reduce circulating phytanic acid. Rapid weight loss and fasting should be avoided, as mobilization of fat stores can release stored phytanic acid and precipitate acute neurological or cardiac crises. With early diagnosis and consistent dietary management, prognosis can be significantly improved, though existing damage to the retina and nerves may be irreversible.

Also known as:

Clinical phenotype terms— hover any for plain English:

AnosmiaHP:0000458MiosisHP:0000616
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Adult Refsum disease.

View clinical trials →

No actively recruiting trials found for Adult Refsum disease at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Adult Refsum disease community →

Specialists

23 foundView all specialists →
SM
Susanna A McRae
CHARLOTTE, NC
Specialist
1 Adult Refsum disease publication
SG
Sydney Galindez
NEW ORLEANS, LA
Specialist
1 Adult Refsum disease publication
EL
Emily Laurent
NEW ORLEANS, LA
Specialist
1 Adult Refsum disease publication
RR
Raúl Y Ramos-Sánchez
Specialist
1 Adult Refsum disease publication
JL
José J López-Fontanet
Specialist
1 Adult Refsum disease publication
NI
Natalio Izquierdo
Specialist
1 Adult Refsum disease publication
JL
Jeffrey J Li
Specialist
1 Adult Refsum disease publication
JK
Jane J Kim
Specialist
1 Adult Refsum disease publication
FN
Fauzia Nausheen
Specialist
1 Adult Refsum disease publication
CL
Catherine Liu
Specialist
1 Adult Refsum disease publication
DH
David Hinkle
Specialist
1 Adult Refsum disease publication
CL
Chen Yu Jamie Lee
Specialist
1 Adult Refsum disease publication
ME
Mark D Elliott
Specialist
1 Adult Refsum disease publication
AL
Anna Lehman
Specialist
1 Adult Refsum disease publication
MF
Myriam Farah
Specialist
1 Adult Refsum disease publication
AM
Adeline Vanderver, MD
Los Angeles, California
Specialist

Rare Disease Specialist

PI on 4 active trials1 Adult Refsum disease publication
KP
Kenneth Setchell, PhD
Specialist
PI on 1 active trial
NM
Nancy Braverman, PhD, MD
BALTIMORE, MD
Specialist
PI on 1 active trial
NM
Nancy E Braverman, MD, MS
BALTIMORE, MD
Specialist
PI on 2 active trials
TP
Todd Durham, PhD
Specialist
PI on 1 active trial
EB
Elise Beausoleil
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Adult Refsum disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Adult Refsum diseaseForum →

No community posts yet. Be the first to share your experience with Adult Refsum disease.

Start the conversation →

Latest news about Adult Refsum disease

Disease timeline:

New recruiting trial: Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study

A new clinical trial is recruiting patients for Adult Refsum disease

New recruiting trial: Spastic Paraplegia - Centers of Excellence Research Network

A new clinical trial is recruiting patients for Adult Refsum disease

New recruiting trial: Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia

A new clinical trial is recruiting patients for Adult Refsum disease

New recruiting trial: The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4

A new clinical trial is recruiting patients for Adult Refsum disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Adult Refsum disease

What is Adult Refsum disease?

Adult Refsum disease (ARD), also known as classic Refsum disease, heredopathia atactica polyneuritiformis, or phytanic acid storage disease, is a rare inherited disorder of lipid metabolism caused by the accumulation of phytanic acid in blood and tissues. The condition results from a deficiency of the peroxisomal enzyme phytanoyl-CoA hydroxylase (encoded by the PHYH gene) or, less commonly, defects in the PEX7 gene, which is required for importing the enzyme into peroxisomes. Phytanic acid, a branched-chain fatty acid derived exclusively from dietary sources (dairy products, ruminant fats, and

How is Adult Refsum disease inherited?

Adult Refsum disease follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Adult Refsum disease?

23 specialists and care centers treating Adult Refsum disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.